Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Kintor Pharmaceutical Ltd ( (HK:9939) ) is now available.
Kintor Pharmaceutical Limited announced the successful completion of a clinical observational study evaluating the efficacy and safety of KX-826 in combination with minoxidil for treating androgenetic alopecia (AGA) in male adults in China. The study demonstrated superior efficacy of the combination treatment over minoxidil monotherapy, with significant improvements in hair count and growth assessments. The results support the optimization of a future phase III clinical trial, potentially enhancing Kintor’s position in the hair loss treatment market.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. The company is involved in developing innovative treatments, particularly in the area of hair loss, with a market focus on male adults in China.
YTD Price Performance: 23.71%
Average Trading Volume: 3,751,200
Technical Sentiment Signal: Buy
Current Market Cap: HK$528.3M
Find detailed analytics on 9939 stock on TipRanks’ Stock Analysis page.